These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3543585)

  • 1. Glucagon-like peptide-1 and the entero-insular axis in obese hyperglycaemic (ob/ob) mice.
    Bailey CJ; Flatt PR
    Life Sci; 1987 Feb; 40(6):521-5. PubMed ID: 3543585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucoregulatory effects of bombesin in lean and genetically obese hyperglycaemic (ob/ob) mice.
    Bailey CJ; Flatt PR
    Comp Biochem Physiol B; 1987; 88(1):359-62. PubMed ID: 3315420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of plasma immunoreactive glucagon in obese hyperglycaemic (ob/ob) mice.
    Flatt PR; Bailey CJ; Buchanan KD
    J Endocrinol; 1982 Nov; 95(2):215-27. PubMed ID: 6757362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The entero-insular axis: the new incretin candidate glucagon-like peptide-1(7-36)amide (GLP-1(7-36))amide].
    Göke R; Göke B; Richter G; Arnold R
    Z Gastroenterol; 1988 Nov; 26(11):715-9. PubMed ID: 2849249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes.
    Jimenez-Feltstrom J; Salehi A; Meidute Abaraviciene S; Henningsson R; Lundquist I
    Regul Pept; 2011 Oct; 170(1-3):43-51. PubMed ID: 21620903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased sensitivity to insulin-releasing and glucoregulatory effects of dynorphin A1-13 and U 50488h in ob/ob versus lean mice.
    Khawaja XZ; Green IC; Thorpe JR; Bailey CJ
    Diabetes; 1990 Oct; 39(10):1289-97. PubMed ID: 1976559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma glucose and insulin response to glucagon and arginine in Aston ob/ob mice: evidence for a selective defect in glucose-mediated insulin release.
    Flatt PR; Bailey CJ
    Horm Metab Res; 1982 Mar; 14(3):127-30. PubMed ID: 7040198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagonlike peptide I (7-37) actions on endocrine pancreas.
    Weir GC; Mojsov S; Hendrick GK; Habener JF
    Diabetes; 1989 Mar; 38(3):338-42. PubMed ID: 2645190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.